ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
S. Zalvidea, L. Andre, X. Loyer, C. Cassan, Y. Sainte-Marie, J. Thireau, I. Sjaastad, C. Heymes, J.-L. Pasquie, O. Cazorla, F. Aimond and S. Richard
Pages 206-217 (12)
Prevention of adverse cardiac remodeling after myocardial infarction (MI) remains a therapeutic challenge. Angiotensin-converting enzyme inhibitors (ACE-I) are a well-established first-line treatment. ACE-I delay fibrosis, but little is known about their molecular effects on cardiomyocytes. We investigated the effects of the ACE-I delapril on cardiomyocytes in a mouse model of heart failure (HF) after MI. Mice were randomly assigned to three groups: Sham, MI, and MI-D (6 weeks of treatment with a non-hypotensive dose of delapril started 24h after MI). Echocardiography and pressure-volume loops revealed that MI induced hypertrophy and dilation, and altered both contraction and relaxation of the left ventricle. At the cellular level, MI cardiomyocytes exhibited reduced contraction, slowed relaxation, increased diastolic Ca2+ levels, decreased Ca2+-transient amplitude, and diminished Ca2+ sensitivity of myofilaments. In MI-D mice, however, both mortality and cardiac remodeling were decreased when compared to non-treated MI mice. Delapril maintained cardiomyocyte contraction and relaxation, prevented diastolic Ca2+ overload and retained the normal Ca2+ sensitivity of contractile proteins. Delapril maintained SERCA2a activity through normalization of P-PLB/PLB (for both Ser16- PLB and Thr17-PLB) and PLB/SERCA2a ratios in cardiomyocytes, favoring normal reuptake of Ca2+ in the sarcoplasmic reticulum. In addition, delapril prevented defective cTnI function by normalizing the expression of PKC, enhanced in MI mice. In conclusion, early therapy with delapril after MI preserved the normal contraction/relaxation cycle of surviving cardiomyocytes with multiple direct effects on key intracellular mechanisms contributing to preserve cardiac function
Angiotensin-converting enzyme inhibitors, excitation-contraction coupling, heart failure, hypertrophy, myofilaments, sarcoplasmic reticulum Ca2+ ATPase, renin-angiotensin system, cardiac remodeling, myocardial infarction, coronary disease, ACE-I therapy, fibrosis, neurohormonal systems, cardiomyocyte phenotype
INSERM U-1046, Physiologie et Medecine Experimentale du Coeur et des Muscles CHU Arnaud de Villeneuve, Bat Andre Crastes de Paulet 371, Rue du doyen G. Giraud, 34295 Montpellier Cedex 5, France.